Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

Abstract: A communication device accurately reports the position a vehicle or a pedestrian with respect to a local vehicle and supports safer driving. The communication device is mounted on a moving body and includes a communication unit that receives communication information according to a preset communication condition, a determination unit that determines whether a service is provided in accordance with the received communication information and a display controller that displays display information needed to provide the service on a map displayed on a display unit, when the service is provided according to a result determined by the determination unit.

Abstract: A communication device accurately reports the position a vehicle or a pedestrian with respect to a local vehicle and supports safer driving. The communication device is mounted on a moving body and includes a communication unit that receives communication information according to a preset communication condition, a determination unit that determines whether a service is provided in accordance with the received communication information and a display controller that displays display information needed to provide the service on a map displayed on a display unit, when the service is provided according to a result determined by the determination unit.

Abstract: A communication device is provided that is capable of accurately reporting which position a vehicle or a pedestrian exists in with respect to the local vehicle and of supporting safer driving. A communication device mounted on a moving body includes: a communication unit that receives communication information according to a preset communication condition; a determination unit that determines whether a service is provided in accordance with the received communication information; and a display controller that displays display information needed to provide the service on a map displayed on a display unit, when the service is provided according to a result determined by the determination unit.

Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

Abstract: A communication device is provided that is capable of accurately reporting which position a vehicle or a pedestrian exists in with respect to the local vehicle and of supporting safer driving. A communication device mounted on a moving body includes: a communication unit that receives communication information according to a preset communication condition; a determination unit that determines whether a service is provided in accordance with the received communication information; and a display controller that displays display information needed to provide the service on a map displayed on a display unit, when the service is provided according to a result determined by the determination unit.

Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

Abstract: An object of the present invention is to provide a compound having strong human S1P2 antagonistic activity in order to develop a useful medicament for therapy of a S1P2-mediated disease such as a disease resulting from vascular constriction, fibrosis and respiratory disease. The compound represented by the general formula (I), wherein all the symbols have the same meanings as described in the specification, has a halogen atom or a haloalkyl group and a phenoxy group at certain substitution sites, and thus has strong human S1P2 antagonistic activity. Therefore, the compound can be a therapeutic agent for a S1P2-mediated disease, such as a disease resulting from vascular constriction, fibrosis and respiratory disease.

Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

Abstract: The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.

Abstract: An object of the present invention is to provide a compound having strong human S1P2 antagonistic activity in order to develop a useful medicament for therapy of a S1P2-mediated disease such as a disease resulting from vascular constriction, fibrosis and respiratory disease. The compound represented by the general formula (I), wherein all the symbols have the same meanings as described in the specification, has a halogen atom or a haloalkyl group and a phenoxy group at certain substitution sites, and thus has strong human S1P2 antagonistic activity. Therefore, the compound can be a therapeutic agent for a S1P2-mediated disease, such as a disease resulting from vascular constriction, fibrosis and respiratory disease.

Abstract: A receiver includes: a broadcast contents acquisition unit configured to acquire contents from a broadcast signal; a determination unit configured to determine whether a received application is an application whose reference to the contents has been permitted; a recording unit configured to record, in a first storage area, an application whose reference to the contents has been determined to have been permitted by the determination unit, and record, in a second storage area, an application whose reference to the contents has been determined not to have been permitted by the determination unit; an execution unit configured to execute the application recorded in at least one of the first storage area and the second storage area; and a reference refusal unit configured to refuse reference to the contents acquired by the broadcast contents acquisition unit due to execution of an application other than the application recorded in the first storage area.

Abstract: The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.

Abstract: A receiving device includes: an output unit configured to output content broadcast from a transmitting device; an application execution unit configured to execute an application; a security policy acquiring unit configured to acquire security policy level data sent from the transmitting device with respect to the application, the security policy level data indicating a sorted level of the application; a policy level acquiring unit configured to acquire policy level data sent from the transmitting device with respect to currently broadcast content, the policy level data indicating a sorted level of the currently broadcast content; a determining unit configured to determine whether or not the application is an application to be controlled, based on the policy level data acquired by the policy level acquiring unit and the security policy data of the application acquired by the security policy acquiring unit; and an application control unit configured to instruct the application execution unit to control the appl

Abstract: The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.

Abstract: A receiver includes: a broadcast reception unit configured to receive a broadcast signal; a communication unit configured to acquire the user identification information by communicating with a terminal device; a policy determination unit configured to read the policy associated with the user identification information from a related data storage unit based on the user identification information acquired by the communication unit, and determine whether or not to permit the access to the data corresponding to the user identification information based on the read policy; a data reading unit configured to read the data corresponding to the user identification information from the related data storage unit in case that the access has been permitted; and an application execution unit configured to start an application according to an application start command included in the broadcast signal and execute the application using the data read by the data reading unit.

Abstract: A reception device includes an access control unit configured to determine whether access to the application programming interface is permitted based on a determination according to the type stored in the application storage unit to correspond to the application identification information set in the call instruction. In addition, the reception device includes a web server unit configured to receive the call instruction from the browser unit, inquire of the access control unit about whether access to the application programming interface is permitted, and control the call instruction according to a result of a determination which is made by the access control unit in response to the inquiry.

Abstract: A receiver includes: a broadcast contents acquisition unit configured to acquire contents from a broadcast signal; a determination unit configured to determine whether a received application is an application whose reference to the contents has been permitted; a recording unit configured to record, in a first storage area, an application whose reference to the contents has been determined to have been permitted by the determination unit, and record, in a second storage area, an application whose reference to the contents has been determined not to have been permitted by the determination unit; an execution unit configured to execute the application recorded in at least one of the first storage area and the second storage area; and a reference refusal unit configured to refuse reference to the contents acquired by the broadcast contents acquisition unit due to execution of an application other than the application recorded in the first storage area.